tiprankstipranks
Advertisement
Advertisement
Passage Bio price target lowered to $15 from $30 at Oppenheimer
PremiumThe FlyPassage Bio price target lowered to $15 from $30 at Oppenheimer
1M ago
Buy Rating Reaffirmed on Encouraging upliFT-D Biomarker Data and Solid Cash Runway Supporting Expanded FTD-GRN Trial
Premium
Ratings
Buy Rating Reaffirmed on Encouraging upliFT-D Biomarker Data and Solid Cash Runway Supporting Expanded FTD-GRN Trial
1M ago
Passage Bio downgraded to Neutral from Outperform at Wedbush
Premium
The Fly
Passage Bio downgraded to Neutral from Outperform at Wedbush
1M ago
Passage Bio reports updated interim data from upliFT-D trial
PremiumThe FlyPassage Bio reports updated interim data from upliFT-D trial
1M ago
Passage Bio initiated with an Outperform at Oppenheimer
Premium
The Fly
Passage Bio initiated with an Outperform at Oppenheimer
2M ago
Passage Bio Ends Hopewell Lab Lease, Extends Cash Runway
Premium
Company Announcements
Passage Bio Ends Hopewell Lab Lease, Extends Cash Runway
2M ago
Passage Bio: Market Overreaction to AAV Oncogenesis Risk Creates Compelling Buy Opportunity Ahead of 2026 PBFT02 Catalysts
PremiumRatingsPassage Bio: Market Overreaction to AAV Oncogenesis Risk Creates Compelling Buy Opportunity Ahead of 2026 PBFT02 Catalysts
4M ago
Passage Bio Highlights PBFT02 Progress and Extended Cash Runway
Premium
Company Announcements
Passage Bio Highlights PBFT02 Progress and Extended Cash Runway
4M ago
Two new option listings and eighteen option delistings on December 22nd
Premium
The Fly
Two new option listings and eighteen option delistings on December 22nd
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100